☆ 4.7 Review

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies

FRONTIERS IN PHARMACOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients

Anna K. Tietjen et al.

Summary: This study found that a dose of 300 mg twice daily of linezolid may not be sufficient to treat patients with multidrug-resistant tuberculosis from a pharmacokinetic/pharmacodynamic perspective. It is therefore recommended to start with a higher dose of 600 mg twice daily to ensure PK/PD target attainment. Therapeutic drug monitoring and MIC determination should be performed to control PK/PD target attainment due to high variability in linezolid's PK in the TB population.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Article Immunology

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Marjorie Z. Imperial et al.

Summary: Limited information is available about optimal linezolid dosing strategies in patients with tuberculosis. We provide practical recommendations about linezolid dosing to minimize severe adverse events.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Respiratory System

Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China

Xubin Zheng et al.

Summary: This study investigated the impact of drug exposure and susceptibility on treatment response of multidrug-resistant tuberculosis (MDR-TB). The researchers found that target attainment of TB drugs was associated with treatment response, and identified potential target thresholds for early dose adjustment.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Infectious Diseases

Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid

Sarah Kim et al.

Summary: This study evaluated the efficacy of clofazimine (CFZ)-containing two-drug regimens with pretomanid (PMD), bedaquiline (BDQ), or linezolid (LZD) for the treatment of tuberculosis. The results showed synergistic effects when CFZ was combined with PMD, BDQ, and LZD against Mycobacterium tuberculosis in different metabolic states. The combination regimens demonstrated greater bacterial kill than the individual drugs. CFZ alone had the weakest antimicrobial efficacy among the evaluated drugs, and the correlation between the mode of interaction and the extent of bacterial kill was not significant.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

Add to Collection

Article Immunology

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

Saskia E. Mudde et al.

Summary: By combining the evaluation of treatment efficacy of anti-tuberculosis drug regimens in a mouse tuberculosis infection model with mathematical modeling, it was found that BPaMZ had a higher treatment-shortening potential than BPaL, compared to the standard HRZE regimen. Treatment with BPaMZ for 6 weeks was sufficient to achieve cure in all mice, while BPaL and HRZE required longer treatment duration to achieve similar cure rates. Mathematical model predictions showed that BPaMZ had a significantly shorter predicted time to 95% probability of cure compared to BPaL and HRZE.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Mike Marvin Ruth et al.

Summary: The study evaluated the efficacy of current treatment regimens for Mycobacterium avium complex and found them to be ineffective, suggesting the need for development of new treatment regimens to be compared in dynamic models.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Critical Care Medicine

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis The COMRADE Randomized, Phase 2A Clinical Trial

Veronique De Jager et al.

Summary: This study aimed to evaluate the efficacy of different doses of meropenem, with or without rifampin, in the treatment of tuberculosis. The study found that a total daily dose of 6 g of meropenem had stronger bactericidal activity compared to a lower dose of 3 g. However, the tolerability of intravenous meropenem was poor, raising concerns about its utility in second-line regimens.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Add to Collection

Review Microbiology

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Jan Heyckendorf et al.

Summary: Despite advancements in diagnostics, drugs, and regimens, tuberculosis remains a major global health threat. The current methods for monitoring TB treatment and determining treatment success have limitations. However, molecular technologies and assays show promise as suitable alternatives, which can potentially revolutionize TB therapy monitoring and expedite drug development.

CLINICAL MICROBIOLOGY REVIEWS (2022)

Add to Collection

Review Microbiology

Anti-tuberculosis treatment strategies and drug development: challenges and priorities

Veronique A. Dartois et al.

Summary: Despite two decades of research, uncertainties in understanding and curing tuberculosis disease continue to hinder progress. However, collaborative efforts between academia, the pharmaceutical industry, and non-profit organizations have resulted in a promising drug candidate pipeline. This review explores the challenges and benefits of standardized regimens versus individualized therapy and highlights the need for markers of disease progression, drug response, and predictors of relapse, as well as in vitro tools and animal models for evaluating new regimens. Additionally, it discusses the importance of prioritizing drug combinations for clinical trials and redesigning trial designs to expedite regimen development.

NATURE REVIEWS MICROBIOLOGY (2022)

Add to Collection

Article Microbiology

Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis

Hasmik Margaryan et al.

Summary: Combination therapy has shown some success in limiting drug-resistant tuberculosis by simultaneously acting on different targets and pathways. It also helps in shortening the duration of therapy. Systems biology approaches are used to analyze the cellular processes of mycobacteria and identify the networks and pathways associated with M. tuberculosis infection and survival. However, the most predictive combination of preclinical models for assessing clinical treatment efficacy remains unclear.

MICROORGANISMS (2022)

Add to Collection

Article Infectious Diseases

Pharmacometrics in tuberculosis: progress and opportunities

Justin J. Wilkins et al.

Summary: This clinical review explores the application potential and opportunities of pharmacometrics in tuberculosis pharmacotherapy.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

Add to Collection

Article Infectious Diseases

Clinical standards for the dosing and management of TB drugs

J. W. C. Alffenaar et al.

Summary: This article presents clinical standards for dosing and management of TB drugs, aiming to guide clinicians and program managers in planning and implementing locally appropriate measures for optimal treatment and improved patient care.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2022)

Add to Collection

Article Microbiology

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Suresh Mallikaarjun et al.

Summary: PK/PD analysis was conducted to determine the efficacy of delamanid in patients with MDR-TB, with once-daily dosing showing feasibility and less impact on QTcF prolongation. The cumulative fraction of response for both 100 mg BID and 200 mg QD doses of delamanid in MDR-TB patients was close to or above 90%.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Immunology

Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response

Xubin Zheng et al.

Summary: This study aimed to identify clinically relevant PK/PD thresholds for tuberculosis treatment optimization. Using CART analysis and LASSO logistic regression, the study found that AUC/MIC values and drug exposure of TB drugs were associated with clinical outcomes and adverse events. Further research is needed to explore the impact of CART-derived thresholds for individualized dosing on treatment outcomes in randomized controlled trials.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva

Jan-Willem C. Alffenaar et al.

Summary: A simple, low-cost, and robust TDM method using mobile UV/VIS spectrophotometry to quantify Levofloxacin in human saliva has been developed for TB endemic settings. The method can be used for personalized dose adjustment in identifying patients with low Levofloxacin drug exposure.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study

Kendra K. Radtke et al.

Summary: The study identified the optimal rifapentine dose for a 6-week monotherapy regimen and predicted clinical efficacy, suggesting that a 600-mg daily dose for 6wP may result in equal or better efficacy than 1HP and 3HP for LTBI treatment, without the potential added toxicity of isoniazid.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

Shashikant Srivastava et al.

Summary: The combination of tedizolid, moxifloxacin, and faropenem showed effective killing of nonreplicating persisters (NRP) of Mycobacterium tuberculosis. There was no significant difference in efficacy compared to the standard TB regimen, and no emergence of drug resistance was observed in the study. Further clinical studies are needed to validate these findings.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Vancomycin’s potency against Mycobacterium tuberculosis in the hollow fiber system model

Shashikant Srivastava et al.

Journal of Global Antimicrobial Resistance (2021)

Add to Collection

Review Pharmacology & Pharmacy

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

Marieke G. G. Sturkenboom et al.

Summary: Tuberculosis remains the leading cause of death from infectious diseases, with the pharmacokinetics and pharmacodynamics of anti-TB drugs playing a crucial role in treatment optimization. Population pharmacokinetic models and Bayesian dose adjustment can be utilized to optimize treatment and prevent slow response, acquired drug resistance, and adverse effects. The development of therapeutic drug monitoring for TB relies on academic and clinical collaborations for future advancements in this field.

CLINICAL PHARMACOKINETICS (2021)

Add to Collection

Review Pharmacology & Pharmacy

From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotic

Sebastian G. Wicha et al.

Summary: Therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD) are crucial for individualized dosing in critically ill patients with infections. The use of MIPD software and new technologies has the potential to revolutionize antibiotic dosing, but more clinical trials are needed to validate their effectiveness.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Respiratory System

Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg-1 rifampicin

Lindsey H. M. te Brake et al.

Summary: The study evaluated the safety, tolerability, pharmacokinetics, and early bactericidal activity of increasing doses of rifampicin in treatment-naive adult smear-positive patients with tuberculosis. While the 50mg/kg dose showed an increased bactericidal effect, it was not well tolerated, leading to treatment discontinuations, whereas the 40mg/kg dose was well tolerated and selected for further evaluation.

EUROPEAN RESPIRATORY JOURNAL (2021)

Add to Collection

Article Immunology

Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model

Elise D. Pieterman et al.

Summary: The study compared the efficacy of an all oral drug regimen (BDL) with a standard regimen (HRZE) on the mycobacterial load in the lungs and spleen of tuberculosis-infected mice, showing that BDL was more effective and could be a valuable option for the treatment of drug-resistant tuberculosis.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Pharmacology & Pharmacy

The Treatment of Tuberculosis

Charles A. Peloquin et al.

Summary: Tuberculosis is a major cause of infectious death worldwide, with treatment divided into latent and active stages. Drug regimens must consider both bactericidal and sterilizing activities, while drug resistance poses challenges. Selection of drugs without overlapping adverse reactions and overcoming drug penetration into sanctuaries are key issues.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis

Louvina E. van der Laan et al.

Summary: Population pharmacokinetic models were developed for lamivudine and abacavir in HIV-positive children, with no significant difference found in key pharmacokinetic parameters of the drugs when co-administered with routine drugs used for MDR-TB.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis

Shashikant Srivastava et al.

Summary: Cefazolin-avibactam combination has shown efficacy against MDR-TB and drug susceptible TB strains in children through PK/PD principles. The optimal dosing strategy was determined based on age-specific CFR and Mtb susceptibility breakpoint, highlighting the potential of repurposing cefazolin for pediatric TB treatment.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Editorial Material Infectious Diseases

The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment

A-G. Martson et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2021)

Add to Collection

Article Infectious Diseases

Saliva-based linezolid monitoring on a mobile UV spectrophotometer

Hannah Yejin Kim et al.

Summary: The study validated the feasibility and accuracy of a UV spectrophotometric assay using non-invasive saliva sampling for linezolid.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis

Lenaig Tanneau et al.

Summary: This study investigated the potential relationships between BDQ and/or its main metabolite (M2) pharmacokinetic metrics and QTcF interval or transaminase levels in patients with MDR-TB. The findings suggest that M2 concentrations were responsible for drug-related QTcF increase, but no concentration dependency for transaminase level elevation was observed. High BDQ exposure at the upper end of the observed range may not be associated with a higher risk of safety events.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)

Add to Collection

Article Microbiology

Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis

Andrew D. Gewitz et al.

Summary: This study aimed to establish a model describing longitudinal TTP, identify characteristics associated with delayed culture conversion time, and explore the factors affecting bacterial clearance by rifapentine. Sensitivity analysis revealed the potential for early detection of exposure-response relationships in phase 2b trials using truncated TTP data.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis

Santosh Wagh et al.

Summary: Despite decades of research, tuberculosis remains a leading cause of death from a single infectious agent. Spectinamides, particularly spectinamide 1810, show promising efficacy and PK/PD relationship in mouse models of tuberculosis. The study found no difference in PK of 1810 in infected vs healthy animals, and the best PK/PD indices for bacterial killing were fC(max)/MIC and fAUC/MIC.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Shashikant Srivastava et al.

Summary: The study showed that cefdinir has potential efficacy against both drug-susceptible and multi-drug resistant tuberculosis, with the ability to kill Mtb strains in both in vitro and pre-clinical models. The pharmacokinetic/pharmacodynamic index AUC(0-24)/MIC of 578.86 was identified as the optimal exposure for sterilizing efficacy. Further clinical validation of these findings is needed.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Infectious Diseases

Determination of Rifampin Concentrations by Urine Colorimetry and Mobile Phone Readout for Personalized Dosing in Tuberculosis Treatment

Claire Szipszky et al.

Summary: This study developed a urine colorimetry method for measuring rifampin concentrations, and used a mobile phone photographic application to predict clinically important serum rifampin pharmacokinetic measurements in children treated for TB. The results showed that the assay accurately measured rifampin absorbance in varying environmental and biological conditions, and was sensitive for detection of low rifampin serum concentrations among children treated for TB.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)

Add to Collection

Article Immunology

Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis

Jan-Willem C. Alffenaar et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Microbiology

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients

Alan Faraj et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development

Budi O. Susanto et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Infectious Diseases

Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?

Jan-Willem C. Alffenaar et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Review Infectious Diseases

How to design a study to evaluate therapeutic drug monitoring in infectious diseases?

A-G Martson et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

Add to Collection

Article Pharmacology & Pharmacy

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example

Lina Keutzer et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Review Health Care Sciences & Services

Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review

Lina Keutzer et al.

JMIR MHEALTH AND UHEALTH (2020)

Add to Collection

Article Health Care Sciences & Services

Medical Device Apps: An Introduction to Regulatory Affairs for Developers

Lina Keutzer et al.

JMIR MHEALTH AND UHEALTH (2020)

Add to Collection

Article Immunology

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children

Shashikant Srivastava et al.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2020)

Add to Collection

Article Infectious Diseases

Once-a-week tigecycline for the treatment of drug-resistant TB

Devyani Deshpande et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Microbiology

Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture

Robin J. Svensson et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis

Robin J. Svensson et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Article Immunology

Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis

Devyani Deshpande et al.

JOURNAL OF INFECTIOUS DISEASES (2019)

Add to Collection

Review Medical Laboratory Technology

Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs

Johanna Kuhlin et al.

CLINICAL MASS SPECTROMETRY (2019)

Add to Collection

Article Critical Care Medicine

Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis

Keertan Dheda et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)

Add to Collection

Article Pharmacology & Pharmacy

Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin

Sebastian G. Wicha et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Immunology

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Robin J. Svensson et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Article Multidisciplinary Sciences

Improving treatment outcome assessment in a mouse tuberculosis model

Bas C. Mourik et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Article Immunology

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis

Devyani Deshpande et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Immunology

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis

Devyani Deshpande et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Immunology

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-esistant Tuberculosis

Devyani Deshpande et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Immunology

D-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal

Devyani Deshpande et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Immunology

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis

Shashikant Srivastava et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Immunology

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs

Tawanda Gumbo et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Biochemistry & Molecular Biology

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Marjorie Z. Imperial et al.

NATURE MEDICINE (2018)

Add to Collection

Article Pharmacology & Pharmacy

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

Robin J. Svensson et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Microbiology

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis

Devyani Deshpande et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

Add to Collection

Review Immunology

Busting the Myth of Static vs Cidal: A Systemic Literature Review

Noah Wald-Dickler et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Infectious Diseases

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Elin M. Svensson et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)

Add to Collection

Article Infectious Diseases

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree et al.

LANCET INFECTIOUS DISEASES (2017)

Add to Collection

Article Immunology

Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model

Gerjo J. de Knegt et al.

TUBERCULOSIS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models

Chunli Chen et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

Add to Collection

Article Medicine, Research & Experimental

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response

I. H. Bartelink et al.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)

Add to Collection

Article Microbiology

Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain

Bas C. Mourik et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Article Microbiology

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing

Sander P. van Rijn et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future

A. S. Darwich et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Microbiology

Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis

Jean-Philippe Lanoix et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Infectious Diseases

A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro

Oskar Clewe et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)

Add to Collection

Article Microbiology

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis

Shashikant Srivastava et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Immunology

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

Devyani Deshpande et al.

CLINICAL INFECTIOUS DISEASES (2016)

Add to Collection

Letter Infectious Diseases

Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements

Marieke G. G. Sturkenboom et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2016)

Add to Collection

Review Chemistry, Analytical

LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs

Anette Veringa et al.

TRAC-TRENDS IN ANALYTICAL CHEMISTRY (2016)

Add to Collection

Article Medicine, General & Internal

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

Shashikant Srivastava et al.

EBIOMEDICINE (2016)

Add to Collection

Article Pharmacology & Pharmacy

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

S. F. Marshall et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis

R. J. Svensson et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)

Add to Collection

Article Microbiology

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis

Marieke G. G. Sturkenboom et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Add to Collection

Article Immunology

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens

Dakshina Chilukuri et al.

CLINICAL INFECTIOUS DISEASES (2015)

Add to Collection

Article Immunology

Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience

Marco Cavaleri et al.

CLINICAL INFECTIOUS DISEASES (2015)

Add to Collection

Article Pharmacology & Pharmacy

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

Abdullah Alsultan et al.

DRUGS (2014)

Add to Collection

Review Infectious Diseases

The early bactericidal activity of antituberculosis drugs

Andreas H. Diacon et al.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)

Add to Collection

Article Infectious Diseases

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

Simbarashe P. Zvada et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)

Add to Collection

Article Microbiology

Thioridazine Pharmacokinetic-Pharmacodynamic Parameters Wobble during Treatment of Tuberculosis: a Theoretical Basis for Shorter-Duration Curative Monotherapy with Congeners

Sandirai Musuka et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)

Add to Collection

Article Infectious Diseases

Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents

A. H. Diacon et al.

CLINICAL MICROBIOLOGY AND INFECTION (2012)

Add to Collection

Article Pharmacology & Pharmacy

Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization

D. H. Vu et al.

CURRENT PHARMACEUTICAL DESIGN (2012)

Add to Collection

Article Medicine, General & Internal

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

Andreas H. Diacon et al.

LANCET (2012)

Add to Collection

Article Critical Care Medicine

Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection

Tianyu Zhang et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

Add to Collection

Article Microbiology

Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling

Shashikant Srivastava et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)

Add to Collection

Review Developmental Biology

Zebrafish Embryos and Larvae: A New Generation of Disease Models and Drug Screens

Shaukat Ali et al.

BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS (2011)

Add to Collection

Editorial Material Immunology

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

Jakko van Ingen et al.

CLINICAL INFECTIOUS DISEASES (2011)

Add to Collection

Review Pharmacology & Pharmacy

In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens

Shashikant Srivastava et al.

CURRENT PHARMACEUTICAL DESIGN (2011)

Add to Collection

Article Infectious Diseases

Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size

J. E. M. de Steenwinkel et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)

Add to Collection

Article Infectious Diseases

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

A. H. Diacon et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)

Add to Collection

Article Microbiology

Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment

Isobella Honeyborne et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2011)

Add to Collection

Article Immunology

Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability

Shashikant Srivastava et al.

JOURNAL OF INFECTIOUS DISEASES (2011)

Add to Collection

Article Microbiology

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

Tawanda Gumbo

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

Add to Collection

Review Chemistry, Medicinal

In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB

Pavan K. Vaddady et al.

FUTURE MEDICINAL CHEMISTRY (2010)

Add to Collection

Article Infectious Diseases

Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis

Jurriaan E. M. de Steenwinkel et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)

Add to Collection

Article Immunology

Efflux-Pump-Derived Multiple Drug Resistance to Ethambutol Monotherapy in Mycobacterium tuberculosis and the Pharmacokinetics and Pharmacodynamics of Ethambutol

Shashikant Srivastava et al.

JOURNAL OF INFECTIOUS DISEASES (2010)

Add to Collection

Article Microbiology

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

Tawanda Gumbo et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)

Add to Collection

Article Microbiology

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

Tawanda Gumbo et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)

Add to Collection

Article Microbiology

Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

Tawanda Gumbo et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)

Add to Collection

Article Immunology

Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth

Tawanda Gumbo et al.

JOURNAL OF INFECTIOUS DISEASES (2007)

Add to Collection

Article Microbiology

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance

T Gumbo et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)

Add to Collection

Article Immunology

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

T Gumbo et al.

JOURNAL OF INFECTIOUS DISEASES (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.